

Adverse drug reactions are a major problem for healthcare services, the pharmaceutical industry and regulators. This has been highlighted recently with some high-profile drug withdrawals and regulatory decisions. There is an urgent need to develop strategies to reduce the burden of adverse drug reaction – this needs to apply to both drug development (to reduce the rate of attrition) and during clinical use (to reduce patient morbidity, mortality, costs to healthcare, and drug withdrawals). Although there are many factors involved in the causation of adverse drug reactions, and hence in the processes that will be needed to improve drug safety, pharmacogenomics is an important technology that could provide major benefits. The promise of pharmacogenomics in preventing adverse drug reactions has already been witnessed through studies on glucose-6-phosphate dehydrogenase deficiency and haemolysis associated with antimalarials, TPMT testing and 6-mercaptopurine toxicity and HLA-B\*5701 genotyping and abacavir hypersensitivity.

The ESF-UB Conference on Pharmacogenomics will concentrate on adverse drug reactions this year, providing an interactive forum for both senior and junior researchers to learn about the latest developments in safety pharmacogenomics.

## RESEARCH CONFERENCES

ESF-UB Conference in Biomedicine

# Pharmacogenetics and Pharmacogenomics: Adverse Drug Reactions

Hotel Eden Roc, Sant Feliu de Guixols (Costa Brava) • Spain

27 June - 2 July 2008

With support from

 Generalitat de Catalunya  
Departament d'Innovació,  
Universitats i Empresa  
**Comissionat per a Universitats  
i Recerca**



**Chair:** Munir Pirmohamed, University of Liverpool, UK

**Co-Chair:** Laurent Becquemont, Hôpital Bicêtre, Paris, FR

### Invited Speakers will include

Juan Pablo Albar, ProteoRed, Madrid, ES  
Raul Andrade, Malaga U., ES  
Phillipe Beaune, INSERM Paris, FR  
Alasdair Breckenridge, MHRA London, UK  
Philippe Broët, U. Paris-Sud, Villejuif, FR  
Lon Cardon \*, Oxford U., UK  
Yoseph Caraco, Hadassah U. Hospital, IL  
Ingolf Cascorbi, UK-SH, Kiel, DE  
Gianpiero Cavalleri, RCSI, Dublin, IE  
Panos Deloukas, Sanger Institute, Hinxton, UK  
Michel Eichelbaum, IKP Stuttgart, DE  
Felix Frueh, FDA Silver Springs, US  
Arlene Hughes, GlaxoSmithKline, US  
Dyfrig Hughes, Bangor U., UK

Dietrich Keppler, DKFZ Heidelberg, DE  
Jeantine Lunshof, VUMC Amsterdam, NL  
Duncan McHale, Pfizer, Sandwich, UK  
William Ollier \*, Manchester U., UK  
Munir Pirmohamed, Liverpool U., UK  
Werner Pichler \*, Bern U. Hospital, CH  
Jean-Claude Roujeau \*, INSERM Paris, FR  
Francis Rousseau, IntegraGen, Evry, FR  
Andrew Somogyi, Adelaide U., AU  
David Tregouet, INSERM Paris, FR  
Geoff Tucker, Sheffield U., UK  
Bernard Walther, Servier, Orléans, FR  
David Wishart \*, Alberta U., CA

\* To be confirmed

**Application Form & Programme** available from

**[www.esf.org/conferences/08269](http://www.esf.org/conferences/08269)**

**Closing Date for Application 30 March 2008**

European Science Foundation | Research Conferences Unit  
149 avenue Louise | Box 14 | Tour Generali, 15th Floor | Brussels | Belgium  
Tel: + 32 (0)2 533 2020 | Fax: +32 (0)2 538 8486  
Email: [conferences@esf.org](mailto:conferences@esf.org) | [www.esf.org/conferences](http://www.esf.org/conferences)

**[www.esf.org](http://www.esf.org)**